Lotus Eye Hospital and Institute per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹0.08₹0.04₹0.36₹1.40₹1.96
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹0.08₹0.04₹0.36₹1.40₹1.96
₹28.92₹28.92₹28.85₹28.57₹27.69
₹27.53₹25.83₹23.83₹23.18₹22.62
—₹1.51₹2.38₹2.73₹2.11
−₹4.76−₹4.76₹0.06₹0.02₹0.62
—₹0.01₹0.01₹0.50₹0.50
2.12.12.12.12.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

LOTUSEYE₹110.00

Lotus Eye Hospital and Institute Limited

· Pharma & Health
₹ CrorePeersGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹229 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS1.961.400.360.040.08
Diluted EPS1.961.400.360.040.08
Book Value per Share27.6928.5728.8528.9228.92
Revenue per Share22.6223.1823.8325.8327.53
Cash Flow per Share2.112.732.381.51—
Free Cash Flow per Share0.620.020.06-4.76-4.76
Dividends per Share0.500.500.010.01—
Shares Outstanding (cr)2.12.12.12.12.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.